Navigation Links
Vermillion Receives Notice of Allowance for 5th Biomarker Patent Related to Peripheral Artery Disease
Date:11/3/2011

AUSTIN, Texas, Nov. 3, 2011 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a leading molecular diagnostics company, has received a notice of allowance from the United States Patent and Trademark Office for its fifth  patent covering a combination of biomarkers that could be used in the diagnosis of Peripheral Artery Disease (PAD), a condition that raises the risk of heart attack and stroke.

The patent, entitled "Beta-2 Microglobulin (B2m) and C Reactive Protein (CRP) as Biomarkers for Peripheral Artery Disease," involves a unique combination of B2m and CRP, two proteins that have been demonstrated in numerous studies to be associated with PAD.

"This patent substantially strengthens our IP portfolio around the development of VASCLIR®, our product under development for diagnosing PAD," said Dr. Eric Fung, Vermillion's chief medical officer, "and the notice of allowance follows the promising top line results we achieved from our recently completed intended use study."

The goal of the study was to develop and validate a biomarker panel applicable to the intended use population. The results have yielded significant insights regarding individual biomarkers. The details of the study and its results will be made public via a formal presentation at an upcoming cardiovascular meeting.  

"This study is an important advancement, " noted Dr. Fung, "since according to the U.S. Department of Health and Human Services, one in every 20 Americans over the age of 50 has PAD."(1)

For additional information about Vermillion, contact Liolios Group at 949-574-3860 or email info@liolios.com.

About Vermillion

Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercializatio
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vermillion Reports Results for the Second Quarter 2011
2. Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent
3. Vermillion Announces Joining Russell Microcap® Index
4. Vermillion Announces Notice of Allowance for Alzheimer Patent
5. Vermillion Announces the Appointment of Bruce Huebner to its Board of Directors
6. Vermillion to Host Conference Call to Present Company Update and Review Financial Results for the First Quarter 2011
7. Stephens Initiates Coverage on Vermillion
8. Vermillion Announces Notice of Allowance of Patent for Breast Cancer Biomarkers
9. Vermillion Announces Issuance of European Patent
10. Vermillion to Attend Society of Gynecologic Oncologists Meeting March 15-19
11. Medicare Establishes Reimbursement Coverage for Vermillions OVA1(TM) Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015  Today, Americord Registry, one ... announced Andrew Horne , a partner at Kirkland & ... Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   ... Americord,s Advisory Board," says Martin Smithmyer , CEO of ... his legal career that will assist Americord,s growth and vision." ...
(Date:6/30/2015)... ... June 30, 2015 , ... With ... not sacrifice selectivity to achieve faster flow rates in comparison to nylon or ... significant open space to allow easy liquid flow while trapping particulates as small ...
(Date:6/30/2015)... ... , ... The maximum number of shares proposed to be purchased in the ... unvested restricted stock). On June 29, 2015, the last trading day prior to the ... the OTCBB was $2.29 per share. , The tender offer will expire on July ...
(Date:6/30/2015)... DIEGO , June 30, 2015  The ... Education in Biosciences (CCE/Bio) and UC San Diego ... fermentation, to be held Aug.  12 – 14, ... ).  This three-day workshop provides an intense exposure ... industrial biotechnology, and is well-suited to biologists, process ...
Breaking Biology Technology:Americord Registry Announces Andrew Horne as Advisory Board Member 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2
... Key Secondary Endpoints,NEW YORK, March 10 Intra-Cellular Therapies, ... Phase II trial in patients with Sleep Maintenance Insomnia ... increased slow wave sleep and decreased the duration of ... meeting the prespecified primary and key secondary endpoints of ...
... March 9 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ... positive clinical study results for its Bio-Seal(TM) Lung ... Interventional Radiologists Annual Scientific Meeting in San Diego, ... of Bio-Seal in patients undergoing lung biopsy procedures ...
... 9 Former Presidential candidate Gary Bauer on Monday called ... embryonic stem cell research "evidence that ideology is the goal ... a tragedy, as lives will be lost and not saved ... Values made the following statement: "It,s tragic that Barack Obama ...
Cached Biology Technology:Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 2Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 3Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 4Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 5Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 6Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 7Angiotech announces positive results from Bio-Seal(TM) clinical study 2Angiotech announces positive results from Bio-Seal(TM) clinical study 3Angiotech announces positive results from Bio-Seal(TM) clinical study 4Angiotech announces positive results from Bio-Seal(TM) clinical study 5
(Date:6/26/2015)... ATL Technology, LLC, a top provider of electromechanical ... use solutions, headquartered in Springville, Utah , ... California corporation with locations in Santa ... Rica ). This acquisition will incorporate MedConx,s ... ATL Technology,s existing facility in Costa Rica ...
(Date:6/24/2015)... 24, 2015 This report provides market analysis ... six years. It contains an analysis of the drivers, ... their impact from the short, medium, and long term ... industry, market, and technology trends that currently, prevail in ... concerned authorities to efficiently manage the increasing marine traffic ...
(Date:6/23/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/vq2k2f/bodyworn ... "Body-Worn Temperature Sensors Market - Global Industry Analysis, ... 2020" report to their offering. ... body-worn temperature sensors market. The global body-worn temperature ... of types, care setting, patient demographic, applications and ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... A team from the National Institute of Standards ... Guard on a coordinated effort to train emergency first ... securing reliable samples of suspected biothreats. The project, dubbed ... first responders at the state, local and federal levels ...
... in the journal Annals of Botany , Professor Douglas ... in the ground could harvest more carbon from the air, ... levels. In principle, any crops could be treated in ... for the environment. Although the amount of carbon presently ...
... Nobel Prize for nerve growth factor was awarded more than ... use growth factor clinically. University of Pittsburgh Professor Yadong ... factor to regrow blood vessels. His research, which could be ... death in the Western world, is published this week in ...
Cached Biology News:Operation Vigilant Sample: First responder training for suspicious powders 2Crop breeding could 'slash CO2 levels' 2Regrowing blood vessels with a potent molecule 2Regrowing blood vessels with a potent molecule 3Regrowing blood vessels with a potent molecule 4
... performance spectral scanning multimode reader with ... advanced SkanIt Software it offers superior ... assay development. Varioskan provides unlimited wavelength ... and photometric assays and a dispenser ...
Angiotensin Converting Enzyme [Porcine Kidney, ACE, Peptidyl-dipeptidase A]...
... Effectively condenses and traps a wide variety of ... pump oil. Easy-to-use glass condensation flask (GCF400) allows ... contained jar for easy draining. Rapid cooling time ... glass flask for quick solvent changes ...
... Assays in Tris buffer, pH 10.2 give ... buffer system. Assays in diethanolamine buffer, pH ... the glycine buffer system. Protein determined by ... buffer salts Preparation Unit Definition: One unit ...
Biology Products: